...WEDNESDAY Sept. 28 (HealthDay News) -- A new study shows that levels ...While the finding is preliminary it could suggest a possible link bet... We've known for some time that significant sleep deprivation has nega...The findings were released online in advance of publication in an upco...

WEDNESDAY, Sept. 28 (HealthDay News) -- A new study shows that levels of amyloid beta, a byproduct of brain activity that is considered a marker for Alzheimer's disease, normally rise during the day and decrease at night.

While the finding is preliminary, it could suggest a possible link between sleep deprivation and people's risk for developing the brain-robbing disease, researchers say.

"We've known for some time that significant sleep deprivation has negative effects on cognitive [brain] function comparable to that of alcohol intoxication," Dr. Stephen Duntley, professor of neurology and director of Washington University's Sleep Medicine Center, said in a university news release. "But it's recently become apparent that prolonged sleep disruption and deprivation can actually play an important role in pathological processes that underlie diseases. This connection to Alzheimer's disease isn't confirmed yet in humans, but it could be very important."

The findings were released online in advance of publication in an upcoming print issue of Archives of Neurology.

According to the researchers, levels of the amyloid beta protein do seem to ebb and flow.

"In healthy people, levels of amyloid beta drop to their lowest point about six hours after sleep, and return to their highest point six hours after maximum wakefulness," Dr. Randall Bateman, associate professor of neurology at Washington University School of Medicine in St. Louis, explained in the news release.

"We looked at many different behaviors, and the transitions between sleep and wakefulness were the only phenomena that strongly correlated with the rise and fall of amyloid beta in the spinal fluid," he added.

Bateman and colleagues also found this pattern was most prevalent in healthy, young people and less pronounced in older adults who suffer from shorter or more disrupted periods of sleep.

They suggested the reason for this may be that the brain's low activity during sleep allows the body to clear amyloid beta through the spinal fluid.

Levels of amyloid beta in older adults with Alzheimer's appear to be constant, suggesting a possible link between lack of sleep and people's odds for developing the disease, the team said.

In conducting the study, the researchers divided study participants into three groups:

People aged 60 and older who tested positive for the presence of amyloid beta plaques in the brain.

People aged 60 and older who did not have amyloid beta plaques.

Healthy people ranging in age from 18 to 60 years.

Using a spinal tap, researchers monitored amyloid beta levels in the participants' spinal fluid every hour for up to 36 hours. During this time, they also videotaped the patients' activities and monitored their brain activity.

In the group with brain plaques, amyloid beta levels remained virtually constant. In the other two groups, however, the levels regularly rose and fell in snake-like waves. The highs and lows of this pattern were much more obvious in younger participants, and flatter in older people.

Although the participants' activities did not have an impact on changes in amyloid beta levels, peaks in their sleep and wakefulness consistently occurred before peaks and drops in amyloid beta levels.

The study authors said that more research is needed to explore how disrupted sleep in young people disrupts the normal ebb and flow of spinal amyloid beta, and how sleep aids may help maintain this wave-like pattern.

"It's still speculation, but there are tantalizing hints that better sleep may be helpful in reducing Alzheimer's disease risk," concluded Duntley. "We know from a number of studies that exercise enhances sleep, and research also has shown that exercise is associated with decreased risk of Alzheimer's. Sleep might be one link through which that effect occurs."

More information

The U.S. National Institute of Neurological Disorders and Stroke has more about Alzheimer's disease.

(Date:12/7/2016)... PRUSSIA, PA (PRWEB) , ... December 07, 2016 , ... ... trials with the announcement that it is one of the early adopters completing EU-U.S. ... Shield Framework is designed to provide companies on both sides of the Atlantic with ...

(Date:12/7/2016)... ... December 07, 2016 , ... Children exposed to secondhand ... at the Icahn School of Medicine at Mount Sinai has found. The study ... young children are exposed to secondhand marijuana smoke, measurable amounts of primary metabolite ...

(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... the largest share of the market in 2016 and ... dominance can be attributed to a large number of ... (US hold the largest share in the patient temperature ... benefits such as reducing loss of blood during surgeries, ...

(Date:12/8/2016)... , Dec. 8, 2016 Allergy Diagnostics ... products and tests that are used to determine ... peanuts, milk, or drugs etc. in the samples ... the immune system. The report on global allergy ... of the market. The report consists of an ...

(Date:12/8/2016)... -- Research and Markets has announced the addition of the ... ... report analyzes the worldwide markets for Endodontic Supplies in US$ Thousand. The report ... Japan , Europe , Asia-Pacific ... Annual estimates and forecasts are provided for the period 2015 through 2022. Also, ...